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In Brief
Nobis et al. generated a RhoA-FRET
biosensor mouse to characterize and
quantify the spatiotemporal distribution
of RhoA activity in native mammalian
tissues in vivo during development and
disease progression. They show that
RhoA activity is tightly regulated during
various normal biological processes and
is co-opted in disease settings, such as
invasive breast and pancreatic cancers.
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The small GTPase RhoA is involved in a variety
of fundamental processes in normal tissue. Spatio-
temporal control of RhoA is thought to govern
mechanosensing, growth, and motility of cells,
while its deregulation is associated with disease
development. Here, we describe the generation of
a RhoA-fluorescence resonance energy transfer
(FRET) biosensor mouse and its utility for monitoring
real-time activity of RhoA in a variety of native tissues
in vivo. We assess changes in RhoA activity during
mechanosensing of osteocytes within the bone and
during neutrophil migration. We also demonstrate
spatiotemporal order of RhoA activity within crypt
cells of the small intestine and during different stages
of mammary gestation. Subsequently, we reveal co-
option of RhoA activity in both invasive breast and
pancreatic cancers, and we assess drug targeting
in these disease settings, illustrating the potential
for utilizing this mouse to study RhoA activity in vivo
in real time.
INTRODUCTION
The prototypical Rho GTPases RhoA, Rac1, and Cdc42 play
key roles in cellular homeostasis, including in the regulation of
cell cycle progression, cell polarity, and cell migration (Hall and274 Cell Reports 21, 274–288, October 3, 2017 ª 2017 The Author(s)
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are molecular switches that cycle between inactive guanosine
diphosphate (GDP)-bound and active guanosine triphosphate
(GTP)-bound states. They are activated by guanine nucleotide
exchange factors (GEFs), inactivated by GTPase-activating pro-
teins (GAPs), and sequestered to the cytoplasm in their inacti-
vated state by guanine nucleotide dissociation inhibitors (GDIs)
(Bishop and Hall, 2000; Cherfils and Zeghouf, 2013; Nobes and
Hall, 1999; Zhang et al., 2016).
RhoA is thought to control actomyosin contractility (Wheeler
and Ridley, 2004) and regulate cell-cell junction integrity (Braga
et al., 1997). RhoA and Rac1 have also been shown to be recip-
rocally active at the edge of moving cells (Machacek et al., 2009).
They act during different modes of migration, with Rac1 activity
associated with mesenchymal migration and RhoA with amoe-
boid migration. Cells can switch between these modes depend-
ing on the surrounding tissue topology, demonstrating the plas-
ticity in Rho family GTPase signaling (Byrne et al., 2016; Friedl
and Alexander, 2011).
Here we focus on RhoA, which is thought to be a key regulator
of normal cellular homeostasis and is often deregulated in a
range of disease states. Eloquent work in Xenopus, Drosophila,
and zebrafish has revealed an intricate interplay and compart-
mentalization of Rho GTPase activity in developmental pro-
cesses (Kardash et al., 2010; Miyagi et al., 2004; Wang et al.,
2010). Deregulation of both upstream and downstream regula-
tors of RhoA in mammalian cells has also been linked to cancer
(Rath and Olson, 2012; Rath et al., 2017; Vennin et al., 2017).
Moreover, the subcellular and spatiotemporal regulation of
RhoA has been associated with invasive pancreatic cancer using.
commons.org/licenses/by/4.0/).
in vivo xenograft models (Timpson et al., 2011), while a differen-
tial balance of Rac1 andCdc42 versus RhoA drives invasion in an
orthotopic model of glioblastoma (Hirata et al., 2012). These
studies have yielded significant insights into the role and regula-
tion of RhoA in complex 3D disease and model organism set-
tings, illustrating the need for a resource to assess the regulation
of RhoA in vivo, both in normal mammalian tissues and in dis-
ease models, independently of transfection-based and allograft
approaches.
Fluorescence resonance energy transfer (FRET) imaging has
emerged as a reliable tool for studying protein-protein interac-
tions (Conway et al., 2017), in particular for transient signaling
events that are difficult to access in vivo using conventional
methods (Heasman et al., 2010). Here we present the generation
of a RhoA-FRET biosensormouse to study the role of RhoA in tis-
sue homeostasis and disease progression in vivo. We provide
spatiotemporal analysis of RhoA activity in a number of tissue-
specfic cellular contexts where RhoA is hypothesized to play a
role, which have, to date, proved challenging to access by con-
ventional biochemical methods or using transfection-based
techniques. We explore the role of RhoA in mechanosensing of
osteocytes in situ, and we visualize RhoA activity in neutrophils
in vivo in response to local tissue damage. These processes
are difficult to recapitulate in an in vitro setting, and they demon-
strate the potential of this mouse to probe the role of spatiotem-
poral regulation of RhoA in cells in their native context. We then
combine the RhoA-FRET mouse with optical imaging windows
(Ritsma et al., 2012, 2013, 2014) and genetically engineered
mouse (GEM) models of cancer to illustrate the fundamental
advances the RhoA-FRET mouse can provide in pre-clinical
imaging in normal or disease conditions.
RESULTS
Generation and Characterization of the RhoA-FRET
Mouse in Normal Tissue
The RhoA-FRET biosensor mouse was generated using a modi-
fied EGFP/mRFP Raichu-RhoA biosensor (Timpson et al., 2011;
Yoshizaki et al., 2003) (Figure 1A). When RhoA is activated, the
RhoA domain of the FRET reporter becomes GTP loaded and
binds to the PKN domain, inducing a conformational change
that leads to FRET between the two fluorophores (Figure 1A),
while GDP loading dissociates the PKN domain binding. The
probe is anchored to the membrane by a CAAX box of Ki-Ras,
allowing for a subcellular readout of RhoA activity. This probe
has been robustly characterized, and its dynamic range has
been established in vitro using dominant-negative (T19N) and
constitutively active (Q63L) mutants (Timpson et al., 2011).
Here, to read out RhoA activity, we used fluorescence lifetime
imaging microscopy (FLIM) of the donor fluorophore EGFP,
which decreases upon FRET and has been validated in a number
of biological contexts (Heasman et al., 2010).
The final targeting vector was generated by inserting a lox-
stop-lox transgene under the control of a CAG promoter into
the Hprt locus. We first generated RhoA-OFF mice, in which
expression of the RhoA-FRET biosensor was conditionally pre-
vented by a transcriptional stop sequence (Figures 1B and 1C).
We subsequently crossed the RhoA-OFF mice to mice express-ing cytomegalovirus (CMV)-Cre recombinase to enable ubiqui-
tous expression of the RhoA-FRET biosensor (termed RhoA-
ON mice). Homozygous offspring of both strains were fertile,
healthy, showed no abnormal defects, and exhibited the ex-
pected Mendelian ratio of hereditary transmission.
In the RhoA-ON mouse, the ubiquitiously expressed biosensor
could readily be imaged at depth in normal mammary gland,
pancreas, intestine, and neutrophils (Figure 1D; Movie S1, organ
z stacks, green; biosensor expression, magenta; second har-
monic generation [SHG] of surrounding extracellular matrix
[ECM]). Western blot analysis of the RhoA-ON mouse demon-
strated lowexpression levelsof thebiosensor inavarietyof tissues
(Figures 1E and 1F; Figures S1A–S1C; Movie S1). RhoA activity
was further confirmed using RhoA-GTP immunofluorescence
(Figure S2). In the skin, active-RhoA-GTP immunofluorescence
is observed in the highly proliferative basal keratinocyte layer of
the inter-follicular epidermis and within the hair follicle, aligning
with RhoA activity observed in the RhoA-FRET-imaged sections.
This is consistent with our previous observation that the
RhoA-effector protein ROCK is activated in these regions of the
skin (Ibbetson et al., 2013).
A more extensive characterization and expression profile
in other organs, or sub-organ-specific settings (Figures S1 and
S3; Movie S1), in the RhoA-OFF mouse illustrates the broad ca-
pacity for RhoA imaging, ranging from imaging endothelial cells
via TEK-Cre andmonitoring beta cells within islets of Langerhans
using RIP-Cre to imaging neurons via NPY-Cre (Figure S3; Movie
S2). The activity of RhoA was also investigated in embryonic skin
explants (embryonic day E14.5–E15.5), extracted as described
previously (Li et al., 2011), by driving the reporter expression in
either keratinocytes using K14-Cre or melanocytes via TyrB-
Cre (Figures S4A–S4C; Movie S3). Since Rac1 activation can
antagonize the activity of RhoA (Hetmanski et al., 2016; Nimnual
et al., 2003), Rac1 and RhoA interplay in melanocyte migration
may also be assessed (Figures S4D–S4F). We next character-
ized RhoA signaling in normal tissue-specific contexts to illus-
trate the detailed subcellular and spatiotemporal resolution
achievable with this RhoA-FRET mouse.
Directional RhoA Activation in Osteocyte Protrusions
during Mechanosensing
RhoA signaling has been implicated in the transduction of me-
chanical signals in osteoblast-like cells (Hamamura et al.,
2012). We therefore wanted to investigate the spatiotemporal
regulation of RhoA signaling in response to mechanical loading
in mature osteocytes, which are embedded in the bone matrix
and are thought to transduce force response through the bone
(Noble, 2008). Driving RhoA-FRET reporter (RhoA-OFF) expres-
sion via the Col1a1.3.6-Cre enabled us to monitor RhoA activity
in osteocytes in the calvaria (Figures 2A and 2B; Figures S5A and
S5B). Using the RhoA-FRET biosensor mouse, we visualized
osteocytes residing within the lacunae of freshly excised calvaria
with protrusions spreading through canaliculi of the bone (Fig-
ures 2A and 2B; Movie S4, panel 1).
To monitor the role of RhoA signaling in the mechanosensing
processes of osteocytes, we applied a compressive force to
sections of calvaria along a defined axis during imaging (Fig-
ure 2C; Figures S5C–S5E, with schematic). We monitored theCell Reports 21, 274–288, October 3, 2017 275
Figure 1. Generation of the RhoA-FRET Biosensor Mouse
(A and B) Schematic of the Raichu-RhoA biosensor (A), targeted to the Hprt locus to generate the RhoA-FRET biosensor mouse (B).
(C) Embryonic stem cell colony expressing the RhoA-FRET biosensor (GFP, green; RFP, red).
(D) RhoA activity in the mammary fat pad, pancreas, intestine, and neutrophils of RhoA-ON mice (RhoA-FRET biosensor, green; collagen-derived second
harmonic generation (SHG) signal, magenta) with corresponding fluorescence lifetime (FLIM) images of RhoA activity (high RhoA activity, blue to green; low RhoA
activity, yellow to red).
(E and F) Expression levels (E) and relative quantification (F) of the RhoA-FRET biosensor detected by immunoblot in different tissues of the RhoA-ON
mouse (n = 3).
Columns, mean; bars, SEM. Scale bars, 50 mm.
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activity of RhoA along the length of individual protrusions, from
the cell body to the process tip, over time, shown as kymographs
(Figures 2D–2G, orange lines marking individual processes). In
the absence of force, no changes in RhoA activity were observed
in the osteocyte processes (Figure 2E). Upon the application of
force (producing an 1% lateral compression), an increase in
RhoA activity was observed in a subpopulation of processes
(Figure 2G, note change in lifetime post-compression, red ar-
rows). Interestingly, this increase in RhoA activity was dependent
on the directionality of the force being applied. Osteocyte pro-
cesses aligned in parallel to the compressive force showed no
significant change in RhoA activity, while processes closer to a
perpendicular angle to the applied force demonstrated signifi-
cant RhoA activation (Figures 2H and 2I). These data reveal
orientation-dependent signaling events that lead to distinct sub-
cellular RhoA activation in response to mechanical force trans-
duction, and, therefore, they demonstrate a mechanosensing
role of RhoA in bone. Manipulation of bone density and reci-
procity to mechanical loading in diseases such as osteoporosis
could, therefore, be assessed using this biosensor mouse in the
context of therapeutic intervention.
Live Tracking of RhoA Activity in Swarming Neutrophils
In Vivo
RhoA activity plays a vital role in cell migration. Here we demon-
strate the ability of the RhoA-FRET biosensor mouse to charac-
terize RhoA activity in highly motile cells, such as neutrophils.
The use of primary neutrophils ex vivo is often hindered by their
short viable lifetime, limiting the utility of transfection-based
in vitro imaging studies (Basu et al., 2002). To investigate the
regulation of RhoA activity during neutrophil swarming in vivo,
we used LysozymeM-Cre (LysM-Cre) to drive expression of the
RhoA-FRET biosensor (RhoA-OFF) in neutrophils. The ear was
injected with inactivated Staphylococcus aureus bioparticles to
enrich the local neutrophil population. We then laser ablated a
resident dendritic cell (DC) to create a local site of tissue damage
and, thus, a chemotactic gradient that attracts neutrophils (Fig-
ures 3A and 3B) (Hampton et al., 2015). Infiltrating neutrophils
were imaged (Figure 3C; Movie S5, panels 2 and 3) and tracked
over time (Figures 3D and 3E, black representing earlier time
points and copper representing later time points; Movie S5,
panel 4).
For each neutrophil, the RhoA activity from the front to the rear
of the cell, relative to the direction of motion, was calculated and
plotted as a kymograph of RhoA activity over time. This showedFigure 2. RhoA Activation in the Protrusions of Osteocytes Is Subject to
the Force Applied
(A and B) Osteocyte-specific expression of the RhoA-FRET biosensor (RhoA-OFF
and associated FLIM images of RhoA activity (B).
(C) Compression apparatus.
(D–G) Time-lapse FLIM of RhoA activity in the osteocyte processes, with intensity
kymographs in the absence (E) and presence (G) of a compressive force applied
(H) Maximum reduction in lifetime observed in each process during compression
the compressive force is indicated by the red arrow. Gray bars, weighted hi
perpendicular (red) to the compression force.
(I) Average change in fluorescence lifetime in osteocyte processes over the tim
(processes in uncompressed cells [blue, n = 15] and compressed cells parallel [p
*p < 0.05, by two-way ANOVA accounting for repeated measures. Scale bars, 25
278 Cell Reports 21, 274–288, October 3, 2017anterior and posterior fluctuations in RhoA activity as the neutro-
phils moved (Figure 3F). Following a methodology for in vitro
tracking of Rac1 activity in neutrophils (Johnsson et al., 2014),
the most active region of the cell was traced, illustrating oscilla-
tions of RhoA activity over time as neutrophils moved toward the
site of tissue damage (Figure 3G, red line: rear, green line: front).
Our in vivo readout of RhoA activity during neutrophil migration is
consistent with previous work monitoring fluctuations of Rac1
activity in vitro during translocation and periodic stalling of pri-
mary neutrophils within chemotactic gradients (Johnsson et al.,
2014). In addition, our data demonstrate that, upon reaching
the site of injury in vivo, neutrophil remodelling of the damaged
site occurs (Movie S5, panels 2 and 3 at 15 min time post-
swarming). We produced a large-scale kymograph of average
RhoA activity of the swarming neutrophil population, as a func-
tion of the distance from the damaged site. This showed a
gradual increase in RhoA activity based on the average activa-
tion level of the neutrophils present in the field of view, as well
as collagen remodelling, as the collective cell population moved
toward the site of damage upon inflammation (Figures 3H and 3I,
collagen-remodelled zonewithin white dashed line). Similar anal-
ysis could be used to map the activity of individual or large pop-
ulations of immune infiltrates or to monitor the deregulation of
immune cell activity in disease settings, such as chronic wound
healing (Kular et al., 2015) or immunotherapy in cancer (Steele
et al., 2016).
Mammary RhoA Activity Cycles during Gestation and
HighRhoAActivity IsCo-opted in InvasiveBreast Cancer
Recent investigations have revealed a key role of the small
GTPase Rac1 in gestational involution (Akhtar et al., 2016). Sim-
ilarily, downstream effectors of RhoA, such as PKN1, have been
shown to play a role during the gestation cycle and lactation
(Fischer et al., 2007). We therefore explored how RhoA signaling
changed during both gestation-induced branching and develop-
ment and in a cancer context. Expression of the RhoA-FRET
biosensor (RhoA-OFF) was controlled by the mouse mammary
tumor virus long terminal repeat (MMTV) driving Cre in the mam-
mary epithelium. Carmine staining revealed no morphological
defects at any stage of development (Figure 4A), and immuno-
histochemistry (IHC) for GFP and RFP confirmed RhoA-FRET
biosensor expression (Figures 4B and 4C). FLIM analysis re-
vealed decreasing RhoA activity during gestation, ranging from
high levels in branching mammary ducts in virgin mice (blue in
the FLIM maps) to a gradual decrease in activity in the alveoliCompressive Forces on the Bone and Is Dependent on the Angle of
) (A, green) driven by Col1a1.3.6a-Cre in the calvaria with SHG signal (magenta)
images (D and F, tracked processes, red) and numbered and respective FLIM
after 5 min (red arrow).
as a function of the angle of the process to the compressive force. Direction of
stogram of lifetime change; dots, individual processes parallel (purple) and
e course, quantified by the fifth percentile of the lifetime across the process
urple, n = 18] and perpendicular [red, n = 13] to the force). Shaded area, SEM;
mm.
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that form during pregnancy (Figures 4D and 4E; quantified in Fig-
ure 4F and Movie S6). RhoA became largely inactive in mature
milk-producing alveoli during lactation and returned to an active
state during mammary involution, which is triggered by weaning,
when alveoli break down and the mammary tissue is remodelled
to resemble virgin morphology (Figure 4E, fourth panel; quanti-
fied in Figure 4F). We then assessed RhoA activity in a cancerous
setting using the polyoma middle-T antigen (PyMT) breast can-
cer model, driven byMMTV (Guy et al., 1992). Mice were imaged
at 109 ± 2 days of age, when robust invasion and metastasis are
known to occur (Lin et al., 2003). Comparing wild-type (WT)
mammary glands to PyMT tissue, we observed a significant
upregulation and co-option of RhoA activity in PyMT-induced
tumors (Figure 4G), known to drive cell motility in invasive can-
cers. The RhoA biosensor mouse could, therefore, be used in
various pre-clinical mouse models to examine emerging Rho
GTPase targeting for the treatment of breast cancer (Rath and
Olson, 2012).
Modulation of RhoA Activity during Pancreatic Cancer
Progression and Metastasis
We have shown previously that RhoA is spatially regulated by
mutant p53 in pancreatic ductal adenocarcinoma (PDAC) cells
stably transfected with the RhoA-FRET biosensor, in an allograft
approach (Timpson et al., 2011). To precisely model cancer
progression in the context of the inherent pancreatic microenvi-
ronment, a GEM model of PDAC was used to examine RhoA
activity over the course of native pancreatic cancer progression.
The RhoA-OFF mouse was crossed to the Pdx1-Cre-driven KC
(KRasG12D/+ alone) and KPC (KRasG12D/+ and p53R172H/+) models
of pancreatic cancer (Hingorani et al., 2003, 2005). In PDAC,
KRasG12D/+ and p53R172H/+ are frequent oncogenic drivers,
which accumulate during disease progression (Figure 5A).
Both models have previously been shown to recapitulate the
human disease histopathology (Biankin et al., 2012), and they
display well-defined disease progression stages from precursor
pancreatic intraepithelial neoplasia (PanINs) to fully developed
invasive and metastatic PDAC, respectively.
Whole-body imaging confirmed that RhoA-FRET reporter
expression could be detected locally in Pdx1-Cre mice, while,
in highly metastatic KPC mice, it was readily observed at both
primary and secondary sites (Figure 5B). Native pancreatic tis-
sue displayed high RhoA activity (Figures 5C and 5D) that couldFigure 3. Neutrophil Swarming In Vivo Reveals Oscillation of RhoA Ac
(A and B) Intravital ear imaging in LysM-Cre; RhoA-OFF mice (A) and timeline of
Medial Art, licensed under the Creative Commons Attribution 3.0 Unported licen
(C) Representative time series of neutrophil migration in vivo.
(D and E) Schematics (D) and tracking (E) of single neutrophils migrating toward
(F) Kymographs of RhoA activity showing RhoA activity from the rear to the fro
computed by averaging spatially from the rear (top) to the front (bottom) of the cell,
distance across the cell and the x axis represents time.
(G) Tracking of spatial position of the maximal RhoA activity from the rear (red) to
maximum RhoA activity.
(H) Bulk kymograph of RhoA activity in the entire neutrophil population shown in th
image (weighted by fluorescence intensity).
(I) Upper panel: kymograph of the associated SHG intensity in the damaged area,
damage zone and time, revealing collagen remodelling and clearance near the dam
Lower panel: individual SHG images at a number of time points are shown. Scal
280 Cell Reports 21, 274–288, October 3, 2017be inhibited by the RhoA inhibitor C3-transferase (Figure 5E,
left andmiddle panels; Figure 5F). Subsequent washout of the in-
hibitor and addition of an activator of RhoA, Calpeptin, reverted
RhoA back to active levels (Figure 5E, right panel). This demon-
strates the capability to monitor changes of RhoA activity
both at the whole-organ and single-cell levels in situ, which we
confirmed by glutathione S-transferase (GST) bead pull-down
assays (Figure 5F).
Next, we assessed RhoA modulation in the progression
of PDAC between 150 and 250 days. In KC tumors, RhoA ac-
tivity was progressively reduced from native pancreatic tissue,
through the PanIN stages to fully developed PDAC (Figure 5G;
Figure S6A). Similarly, in KPCmice, RhoA activity was decreased
through consecutive PanIN stages to fully developed PDAC (Fig-
ure 5H; Figure S6B). We have previously shown that Src activity,
which is known to play a key role in pancreatic cancer metas-
tasis, was spatially regulated in subcutaneous PDAC tumors,
with high activity at the invasive border (Morton et al., 2010; No-
bis et al., 2013). We therefore sought to determine whether RhoA
activity displayed a similar spatial pattern in KPC pancreatic tu-
mors. At the final stage of PDAC progression, the tumor cortex
showed elevated levels of RhoA activity compared to the center
(Figure 5I). Furthermore, metastatic regions in the liver revealed
higher levels of RhoA activity compared to the overall primary tu-
mors (Figure 5J). This is consistent with previous observations
that RhoA activity displays plasticity during tumor progression
or invasion and requires switching of RhoGTPase activity for effi-
cient metastasis (Byrne et al., 2016; Hirata et al., 2012; Huang
et al., 2014; Sahai and Marshall, 2002; Timpson et al., 2011).
We observed distinct spatial regulation of RhoA in PDAC pro-
gression, which could enhance our understanding of drug re-
sponses in vivo and help determine optimal Rho GTPase inter-
vention strategies in this invasive disease (Conway et al., 2014;
Rath and Olson, 2012; Rath et al., 2017; Vennin et al., 2017).
Longitudinal Monitoring of Drug Responses In Vivo
Using Optical Windows Reveals Temporally Distinct
Drug-Targeting Efficacies in Pancreatic and Breast
Cancers
Accurate readouts of drug responses in vivo remains a primary
challenge of pre-clinical testing of anti-cancer drugs (Amornphi-
moltham et al., 2011; Conway et al., 2014, 2017; Weissleder
et al., 2016). Ex vivo imaging of excised tissue is limited to ativity during Migration
experiment to induce neutrophil infiltration (B). (A) was adapted from Servier
se (https://creativecommons.org/licenses/by/3.0/).
the ablation (early time points, black; late time points, brown/orange).
nt of a selection of cells moving toward the damage site over time. This was
as determined by the direction of cell motion (shown in D). The y axis represents
the front (green) of the cells over time, illustrating oscillation in the location of
e image as a function of distance from the damage zone and averaged over the
reading out density of cross-linked collagen, as a function of distance from the
age zone that results in a loss of SHG signal (highlighted by dashed white line).
e bars, 25 mm.
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single time point, and comparison of different animals across
time points constitutes a source of significant biological noise
in the readout of drug-targeting efficacy. To monitor changes
in RhoA activity in the same mouse over time and improve the fi-
delity of drug readouts, we used surgical implantation of abdom-
inal imaging windows (AIWs) and mammary imaging windows
(MIWs) for pancreatic and breast cancer drug-targeting studies,
respectively (Figure 6) (Gligorijevic et al., 2009; Ritsma et al.,
2012, 2013, 2014).
Mice were allowed to develop primary KPC tumors over a
period of 125 ± 22 days, prior to surgical engraftment with
AIWs to allow for intravital PDAC imaging in the abdominal cavity
(Figures 6A and 6B). Here we used erlotinib, a second-genera-
tion epidermal growth factor receptor (EGFR) inhibitor, adminis-
tered in three daily consecutive gavages to mice with developed
primary KPC tumors (Figure 6C). RhoA is often associated with
enhancedmigration of cancer cells and is a downstream effector
of EGFR, which is itself a potential therapeutic target (Ardito
et al., 2012; Navas et al., 2012). Therefore, as a proof of principle,
RhoA activity was tracked over 24 hr in PDAC after erlotinib
administration. Here, robust inhibition was evident at 3 hr after
the final administration, which subequently returned to baseline
levels after 24 hr (Figures 6D and 6E).
Similarly, oral gavagingwith dasatinib, an Src/Abl kinase inhib-
itor that is currently under clinical investigation as an anti-inva-
sive in PDAC (Evans et al., 2012), revealed that dasatinib-based
indirect inhibition of RhoA was maximal after 7 hr and was no
longer observed after 24 hr (Figures 6F and 6G). This real-time
imaging approach represents a fundamental advance in single-
cell drug target validation to optimize in vivo scheduling for
maximum benefit (Dubach et al., 2017; Vennin et al., 2017).
Having demonstrated that RhoA activity was upregulated in
PyMT-driven mammary carcinomas (Figure 4G), PyMT mice
expressing the RhoA-FRET reporter were allowed to develop pri-
mary tumors for up to 86 ± 14 days. MIWs were then surgically
implanted on top of the developed tumors to track drug
response in vivo in a mammary tumor context (Figures 6H–6J;
Movie S6). Subsequent FLIM measurement of RhoA activity al-
lowed us to observe effective inhibition following 2–6 hr of dasa-
tinib administration, which after 24 hr reverted to control levels
(Figures 6K and 6L).
Finally, spatial regulation of RhoA was assessed in intestinal
crypts using AIWs (Figures 7A–7C). A gradient of RhoA activity
along the crypt-villus axis was observed with maximal activity
at the crypt base, decreasing to basal levels at approximately
30 mm (Figures 7C–7E; Figure S7; Movie S7). This suggests a
site-specific role for RhoA signaling in the stem cell compartment
of small intestinal crypts in vivo (Figures 7D and 7E), consistent
with our previous work assessing Rac1 activity in this setting
(Johnsson et al., 2014; Myant et al., 2013). The stem cellFigure 4. Mammary Tissue Displays Differential RhoA Activity during G
(A–C) Carmine and H&E stains (A), GFP (B), and RFP (C) IHC of different stages of g
day 4 of involution, and 109 ± 2 days for PyMT tumors). Scale bars, 500 mm (A) a
(D–G) Imaging of RhoA activity during gestation and in PyMT-driven breast canc
collagen-derived SHG signal, magenta) with associated FLIM images (E) and
formation (G). n = 3 mice per condition, 690 cells in total.
Columns, mean; bars, SEM; *p < 0.05 and **p < 0.01 by unpaired Student’s t tes
282 Cell Reports 21, 274–288, October 3, 2017compartment is often a site of progenitor hyperproliferation
and transformation (Ritsma et al., 2014), and, therefore, Rho
GTPase targeting could be differentially traced in this site-
specific setting and highlights another advantage of the RhoA-
FRET mouse.
Here, we have demonstrated that longitudinal in vivo imaging
using FLIM-FRET through optical windows allows for accurate
monitoring of RhoA and its inhibition in primary tissue or tumors
over time. Detailed knowledge of how specific inhibitors fare in
pre-clinical in vivo settings will allow for the tailoring of more pre-
cisely timed treatment regimens, resulting in the most effective
treatment achievable with each compound.
DISCUSSION
We have described the development of a RhoA-FRET mouse
that ubiquitously (RhoA-ON) or conditionally (RhoA-OFF) ex-
presses a RhoA-FRET biosensor from the Hprt locus in a variety
of tissues. The Hprt locus was chosen in this study for its
uniformly low level of expression, balancing the need for a high
signal-to-noise ratio for intravital FLIM-FRET imaging while
avoiding possible dominant-negative effects caused by exces-
sive overexpression of the biosensor (Erami et al., 2016; Goto
et al., 2013; Johnsson et al., 2014). A modified version of the
intra-molecular Raichu-RhoA reporter containing the EGFP/
mRFP fluorophore pair was used in place of ECFP/YPet (Yoshi-
zaki et al., 2003) to avoid potential problems with recombination
from tandem repeats of related fluorescent protein sequences
during mouse generation (Komatsubara et al., 2015).
The RhoA biosensor used in this study reports on the regula-
tion of RhoA activity by GEF/GAPs in native tissue using the Rai-
chu design. We note that a range of biosensors provide the abil-
ity to read out distinct aspects of RhoA activity (Fritz et al., 2013;
Kardash et al., 2010; Pertz et al., 2006; van Unen et al., 2015;
Yang et al., 2016). Converting other key biosensors to similar
in vivo applications, such as the cytoplasmic DORA sensors
with RhoA binding to a PKN1 domain (van Unen et al., 2015) or
the RhoA-2G biosensor that can report on GDI activity (Fritz
et al., 2013; Pertz et al., 2006), will collectively allow us to test
multiple intricate and subtle changes in upstream and down-
stream cascades of this vital molecular switch.
To characterize our RhoA-FRET biosensor mouse in more
detail, we first examined the regulation of RhoA in normal tissues
prior to disease contexts. Tracking RhoA activity in real time dur-
ing mechanosensing of osteocytes, during migration events of
neutrophils, or during mammary gestation revealed the potential
of the RhoA-FRET biosensor mouse for the dynamic study of
RhoA activity in healthy and disease states, which is difficult
to access using biochemical methods in tissues and in cells
with intricate spatiotemporal and subcellular signaling eventsestation and in PyMT-Driven Cancer
estation (5-week-old virgin, day 6.5 of pregnancy, postnatal day 3 for lactation,
nd 50 mm (B and C).
er. RhoA-OFF mice crossed to MMTV-Cre (D, RhoA-FRET biosensor, green;
quantification of RhoA activity during gestation (F) and PyMT-driven cancer
t. Scale bars, 50 mm.
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governing regulation. We imaged osteocytes in their native bone
matrix to investigate the role of subcellular RhoA signaling in me-
chanotransduction. Here, we revealed that the level of RhoA
activation in the dendritic processes varies strongly depending
on the angle of the process with respect to the force. This sug-
gests that the dendritic processes of osteocytes may function
as mechanotransducers of shear forces following stress in the
fluid-filled lacunae containing the dendritic processes (Burra
et al., 2010; Thi et al., 2013). Furthermore, it has been demon-
strated that lacunae perpendicular to compression experienced
more microdamage than those aligned in parallel (Prendergast
and Huiskes, 1996), potentially resulting in enhanced signal
transduction. This demonstrates the utility of the RhoA-FRET
mouse in subcellular intravital imaging studies of mechanical
loading and disorders of bone remodelling.
The rapid gain in immunotherapy applications in melanoma
(Drake et al., 2014) and other cancers could also benefit from
our capacity to monitor immune infiltration at a subcellular level
in real time (Cooper et al., 2016). In this study, we mapped the
population dynamics of RhoA activity during neutrophil infiltra-
tion to sites of local damage in vivo. The observed oscillations
in RhoA activity during in vivo migration were similar to the oscil-
lations in Rac1 activity in neutrophil migration during in vitro
chemotaxis (Johnsson et al., 2014), further undermining the
crosstalk of these small GTPases in the coordinated migration
of neutrophils. Recent work in pancreatic cancer has empha-
sized the role of tumor-associated neutrophils in metastatic
pancreatic cancer progression, where neutrophil depletion via
CXCR2 inhibition improved T cell infilration and immunotherapy
performance (Steele et al., 2016). Future adaptation of our
neutrophil-swarming analysis could, therefore, be used to allow
for fine-tuned targeting of immune checkpoint inhibiton in this
and other cancer types (Steele et al., 2016).
We next examined RhoA regulation during distinct stages of
mammary tissue gestation, in line with recent investigations of
the role of Rac1 in these processes (Akhtar et al., 2016) and the
described crosstalk between both Rac1 and RhoA in normal tis-
sue and cancer progression (Sahai and Marshall, 2002). Here we
observed inactivation of RhoAover the course of pregnancy up to
lactation, when the lactating alveoli are sealed by tight junctions.
In contrast, we observed activation of RhoA during involution
of the mammary gland, when tissue is extensively remodelled.
We also found a co-option of RhoA activity in a mouse model
of invasive and metastatic breast cancer. Similarly, in line with
recent investigations on the action of the upstream regulator
RhoA GEF-H1 (Cullis et al., 2014), we observed a spatial upregu-Figure 5. RhoA Activity in KPC Tumors Is Upregulated at the Invasive
(A) Progression of pancreatic ductal adenocarcinoma (PDAC) via pancreatic intr
KRas and mutant Trp53 (red) used in the KPC mouse model (adapted from Bard
(B) Whole-body imaging of the RhoA-FRET biosensor (WT, Pdx1-Cre, and KPC).
(C and D) RhoA-FRET biosensor expression (RhoA-OFF) in the pancreas driven
(E) Decreased RhoA activity upon C3-transferase treatment, followed by Calpep
(F) Pancreatic RhoA activity measured by GST-Rhotekin-RBD pull-down.
(G) RhoA activity during KC (KRasG12D/+) tumor progression. nR 3 mice per stag
(H) RhoA activity during KPC (KRasG12D/+ + p53R172H/+) tumor progression (whit
355 cells.
(I and J) Quantification of RhoA activity in late-stage KPC tumor center versus bo
Columns, mean; bars, SEM; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.001
284 Cell Reports 21, 274–288, October 3, 2017lation of RhoA in mouse models of PDAC progression. These
studies emphasize the advantage of genetically encoded FRET
biosensor mice, which can be crossed to GEM cancer models
to readily quantify protein activity in situ while tumors form, prog-
ress, and metastasize in their intact microenvironment.
Having shown that RhoA activity can be co-opted in invasive
and metastatic mammary and pancreatic carcinomas, we used
the RhoA-FRET mouse to directly visualize the inhibition of
RhoA using small molecule inhibitors. We use optical windows
to longitudinally read out RhoA response to treatment, illus-
trating the value of the mouse in optimizing preclinical drug tar-
geting in native tissue microenvironments (Conway et al.,
2014). In the KPC mice, it was observed that dasatinib-induced
RhoA inhibition was delayed relative to the PyMT breast cancer
model. This may reflect organ-specific bioavailability of the drug
or the known difficulty of drug delivery in pancreatic cancer
(Neesse et al., 2013), demonstrating the importance of drug
target validation in disease or organ-specific contexts. More-
over, examining the intra-tumoral heterogeneity of drug
response to treatment could also be investigated in this mouse,
exploiting the high spatial resolution provided by intravital
microscopy for both primary and secondary sites, while tracking
non-responsive subpopulations over time could help understand
the development of resistance in vivo, which is currently poorly
understood in many disease areas.
Lastly, the in vivo distribution, regulation, as well as potential
redundancy of upstream or downstream regulators of RhoA,
such as GEFs, GAPs, and GDIs, could also be investigated in
multiple organ and disease settings (Cerikan et al., 2016; Cherfils
and Zeghouf, 2013; Porter et al., 2016). This could help dissect,
in real time, the complex changes that occur during disease
progression, which, in many cases, do not involve loss or gain
of RhoA activity but rather transient modulation of this vital
molecular switch.EXPERIMENTAL PROCEDURES
Animals
Animals were kept in conventional animal facilities. All experiments were car-
ried out in compliance with guidelines of the UK Home Office, the Australian
code of practice for the care and use of animals for scientific purposes, and
the Garvan Ethics Committee. Mice were kept on a 12-hr day-night cycle
and fed ad libitum.
Drug Treatments
Dasatinib was administered by oral gavage at 10 mg/kg in 80 mmol/L citrate
buffer for three consecutive days before imaging. Erlotinib was administeredBorder and in Liver Metastases
aepithelial neoplasms (PanINs), with reported key drivers highlighting mutant
eesy and DePinho, 2002).
by Pdx1-Cre (C) and GFP and RFP IHC (D).
tin-mediated re-activation of RhoA. n = 3 mice per treatment group, 225 cells.
e, 244 cells.
e arrows, active cells; red arrows, inactive cells). n = 3 mice per tumor stage,
rder (I, n = 4 mice, 168 cells) and liver metastases (J, n = 5 mice, 134 cells).
by unpaired Student’s t test. Scale bars, 50 mm.
Figure 6. RhoA Activity in KPC and PyMT Tumors In Vivo Imaged through Optical Imaging Windows
(A) Schematic of an abdominal imaging window (AIW) implanted into a mouse.
(B) In vivo imaging of a late-stage KPC tumor through an AIW.
(C) Timeline of AIW surgery, subsequent drug treatment regimen, and imaging time points.
(D and E) Live time course (D) and quantification of RhoA activity (E) after 3 daily oral gavages of 100mg/kg erlotinib in vivo in KPC tumors, showing effective RhoA
inhibition after 3 hr. n = 3 mice, 90 cells.
(F and G) Live time course (F) and quantification of RhoA activity (G) after 3 daily oral gavages of 10mg/kg dasatinib in vivo in KPC tumors, showing effective RhoA
inhibition after 7 hr. n = 3 mice, 291 cells.
(H and I) Schematics of a mammary imaging window (MIW) implanted into a mouse (H) on top of a late-stage PyMT-driven mammary tumor (I).
(legend continued on next page)
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Figure 7. Spatially Defined RhoA Activity in the Small Intestine In Vivo Imaged through Optical Imaging Windows
(A–C) Schematics of AIW imaging of the small intestine (A and B) and direction of imaging from the base of the crypts toward the villi (C).
(D and E) In vivo imaging (D) and quantification of RhoA activity (E) in crypts of the duodenum, revealing spatially distinct RhoA inactivation with progression away
from the base of the crypts (white arrows, active cells; red arrows, inactive cells). n = 3, 12 crypts, 255 cells.
Columns, mean; bars, SEM; *p < 0.05 and ***p < 0.001 by unpaired Student’s t test. Scale bars, 50 mm.by single gavage at 100 mg/kg in 0.5% w/v methyl cellulose. C3-transferase
was used at 0.5 mg/mL and Calpeptin at 0.2 U/mL on ex-vivo-imaged
pancreas.
FLIM-FRET Imaging of RhoA-FRET Biosensor
FLIM-FRET measurements were conducted using a Titanium:Sapphire femto-
second pulsed laser and time-correlated single-photon-counting (TCSPC)
equipment. Data were analyzed using LaVision Impector, phasor analysis
with TTTR data analysis software, and FLIMfit.
See the Supplemental Experimental Procedures for more details.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and seven movies and can be found with this article online at
https://doi.org/10.1016/j.celrep.2017.09.022.
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